Compounds for treatment of cancer

1. A compound represented by formula II:

wherein

Q is S, NH, or O;

Z is CH or N;

A is substituted or unsubstituted phenyl; substituted or unsubstituted indolyl; or substituted or unsubstituted indazolyl;

wherein the optional substituents of A include O-alkyl, O-haloalkyl, F, Cl, Br, I, NO 2 , haloalkyl, CF 3 , CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , —SO 2 -aryl, C 1 -C 5 linear or branched alkyl, haloalkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or a combination thereof;

R 1 is independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CF 3 , CN, NO 2 , —CH 2 CN, NH 2 , hydroxyl, COOH, C(O)H, NHCO-alkyl, —O(CH 2 ) j OCH 3 , —O(CH 2 ) j OH, −O(CH 2 ) j NHCH 3 , —O(CH 2 ) j NH 2 , —O—(CH 2 ) j N(CH 3 ) 2 , —OC(O)CF 3 , —OC(O)CH 2 Cl, —OCH 2 Ph, —O(CH 2 ) j NH 2 , —O(CH 2 ) j N-phthalimide or a combination thereof;

R 2 is hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CF 3 , CN, NO 2 , —CH 2 CN, NH 2 , hydroxyl, COOH, C(O)H, NHCO-alkyl, —O(CH 2 ) k OCH 3 , —O(CH 2 ) k OH, —O(CH 2 ) k NHCH 3 , —O(CH 2 ) k NH 2 , —O—(CH 2 ) k N(CH 3 ) 2 , —OC(O)CF 3 , —OC(O)CH 2 Cl, —OCH 2 Ph, —O(CH 2 ) k NH 2 or —O(CH 2 ) k N-phthalimide;

i, j, and k are independently an integer between 0 to 5;

n is an integer between 1 to 4;

or a metabolite, hydrate, isomer, N-oxide, prodrug, pharmaceutical product, pharmaceutically acceptable salt, polymorph, tautomer, or a combination thereof.

2. The compound of claim 1 , wherein R 1 is OCH 3 , n is 3 and R 2 is hydrogen.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is compound 3 represented by the structure:

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is compound 4, 5, 6 or 7:

5. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 , further comprising at least one other anti-cancer agent in addition to the compound of Formula II.

7. The compound of claim 1 , wherein said compound has the formula (VII):

wherein

Z is CH or N;

A is substituted or unsubstituted phenyl; substituted or unsubstituted indolyl; or substituted or unsubstituted indazolyl;

wherein the optional substituents of A are selected from the group consisting of O-alkyl, O-haloalkyl, F, Cl, Br, I, NO 2 , haloalkyl, CF 3 , CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , —SO 2 -aryl, C 1 -C 5 linear or branched alkyl, haloalkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 and combinations thereof;

i is an integer between 0 to 5;

or a metabolite, hydrate, isomer, N-oxide, prodrug, pharmaceutical product, pharmaceutically acceptable salt, polymorph, tautomer, or a combination thereof.